---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-041332"
form_type: "8-K"
ticker: "BJDX"
cik: "0001704287"
company_name: "Bluejay Diagnostics, Inc."
filed_at: "2023-05-19T23:59:59+00:00"
generated_at: "2026-06-14T19:54:16.827188+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Bluejay Diagnostics updates Symphony IL-6 regulatory strategy, expands trial to sepsis patients

## Summary
- Trial widened from severe COVID-19 only to all hospitalized sepsis patients to speed enrollment while maintaining H1 2024 submission timeline.
- Company to submit FDA pre-submission application for revised study design in Q2 2023.
- New indication for risk stratification of hospitalized sepsis patients aligns with recent FDA feedback.

## SEC filing metadata
- accession: 0001213900-23-041332
- form_type: 8-K
- ticker: BJDX
- cik: 0001704287
- company_name: Bluejay Diagnostics, Inc.
- filed_at: 2023-05-19T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1704287/000121390023041332/0001213900-23-041332-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1704287/000121390023041332/ea178902-8k_bluejay.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-041332
- JSON: https://secwatch.observer/filing/0001213900-23-041332.json
- Plain text: https://secwatch.observer/filing/0001213900-23-041332.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.